Clinical trial
Study of CS-1008 in Patients With Advanced Solid Malignancies and Lymphomas…
NCT00320827 · Daiichi Sankyo, Industry · Completed
Key facts
| NCT number | NCT00320827 |
|---|---|
| Title | Study of CS-1008 in Patients With Advanced Solid Malignancies and Lymphomas (Without Leukemic Component) |
| Official title | Phase 1 Study of CS-1008, a Humanized Monoclonal Antibody Targeting Death Receptor 5 (DR5), Administered Weekly to Patients With Advanced Solid Malignancies and Lymphomas (Without Leukemic Component) |
| Lead sponsor | Daiichi Sankyo, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Malignancies, Lymphoma |
| Intervention type | Drug |
| Interventions | CS-1008 (humanized anti-DR5 antibody) |
| Enrollment | 40 |
| First posted | May 3, 2006 |
| Last update posted | Sep 11, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: